A. Optic nerve degeneration B. VEGF overexpression C. Macular destruction D. Photoreceptor degradation

A. 1%-2% B. 2%-5% C. 5%-10% D. 10% to 15%

A. Anti-VEGF therapies are the preferred first-line options over intravitreal corticosteroids injections B. Intravitreal corticosteroid injections are the preferred first-line options over anti-VEGF therapies C. Surgery is preferred over both anti-VEGF therapies and intravitreal corticosteroid injections D. Anti-VEGF therapies and intravitreal corticosteroids injections are interchangeable first-line options

A. Anti-VEGF medications must be administered weekly for the first 6 months of treatment B. Anti-VEGF medications are not expected to interact with any other medications C. Aflibercept and ranibizumab must be compounded prior to each administration D. Anti-VEGF agents only prevent disease worsening, but they do not improve visual acuity

A. Aflibercept B. Bevacizumab C. Ranibizumab D. Triamcinolone